Diagnostic and therapeutic challenge of Aspergillus flavus scleritis.

PURPOSE: To discuss the diagnostic and therapeutic challenges involved in the management of Aspergillus flavus scleritis and present a review of related literature. METHODS: Case report and literature review. RESULTS: A healthy 54-year-old woman presented with a 1-week history of severe pain and redness in her left eye. She was treated with prednisone for presumed idiopathic autoimmune scleritis after extensive evaluation revealed no apparent etiology. While on immunosuppressant therapy, the patient developed a scleral nodule that proved to be a scleral abscess with normal overlying scleral architecture. Culture of the abscess and extensive infectious disease evaluation did not offer an etiologic explanation. Biopsy of a subsequent scleral nodule revealed fungal hyphae on fixed tissue stains, and A. flavus was identified on fungal culture. The patient later acknowledged intravenous drug use in the 2 months preceding her presentation. Oral voriconazole and intravenous caspofungin along with repeated surgical drainage of emerging scleral abscesses eradicated the active disease after 3 months. CONCLUSIONS: Despite its rare occurrence, Aspergillus sp. should be considered as a potential cause of an unusual progressive scleritis. Specific questioning regarding intravenous drug use may prove relevant. Scleral biopsy was instrumental in establishing the diagnosis. Aggressive multidrug medical therapy combined with repeated surgical debridement resulted in a positive clinical outcome.

Recombinant human tumor necrosis factor receptor Fc fusion protein (Etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration.

PURPOSE: To review the efficacy of Etanercept as an alternate therapy for treatment of necrotizing anterior scleritis and sterile corneal ulceration unresponsive to traditional therapies. METHODS: A retrospective review of 10 patients treated with Etanercept for vision-threatening scleritis and sterile corneal ulceration. RESULTS: Etanercept alone or in combination with other immunosuppressive therapies controlled inflammation, arrested tissue ulceration, and in many cases permitted tapering or cessation of toxic immunosuppressive therapies. No complications or systemic toxicity were observed with Etanercept use. CONCLUSION: Etanercept is an effective treatment for scleritis and sterile corneal ulceration and has a favorable benefit-to-risk ratio. It may be considered for therapy of progressive disease or cases that are unresponsive to traditional therapies.

Delayed-onset mycobacterial keratitis after LASIK.

PURPOSE: To describe the time course, diagnosis, clinical features, and treatment of seven patients with Mycobacterium szulgai keratitis that developed from 7 to 24 weeks after laser in situ keratomileusis (LASIK). METHODS: Seven of 30 eyes of 18 patients were identified with keratitis after LASIK. The first two patients presented 12 to 14 weeks after LASIK; nontuberculous mycobacteria were identified 1 month after the flaps were cultured. Patient recall identified three additional cases by culture and two cases by clinical features alone. Pulsed-field gel electrophoresis (PFGE) was used to type the isolates, and treatment was modified based on susceptibilities. RESULTS: M. szulgai was identified in five patients for whom cultures were performed, but response to empiric therapy based on cultures proved unsatisfactory. The keratitis resolved in all patients with treatment including clarithromycin based on susceptibilities. Medical therapy was sufficient, although one patient required flap amputation. Six of seven patients recovered best-corrected visual acuity (BCVA), while one patient lost one line of BCVA. Two patients lost one line of postoperative uncorrected visual acuity (UCVA), two patients gained one line of UCVA, and three patients recovered postoperative UCVA. PFGE analysis revealed that the M. szulgai strains were identical, and the infection source was contaminated ice used to chill syringes for saline lavage. CONCLUSIONS: Nontuberculous mycobacterial keratitis after LASIK is a diagnostic and management challenge, but outcomes can be preserved with treatment based on susceptibilities. This cluster underscores the importance of adherence to sterile protocol during LASIK.